Pacific Biosciences of California, Inc.

As of August 25, 2025, Pacific Biosciences of California, Inc. is in a mildly bearish trend, indicated by bearish MACD and moving averages, with a year-to-date return of -30.05% compared to the S&P 500's 12.22%.

As of April 29, 2021, Pacific Biosciences of California, Inc. is considered a risky investment due to its overvaluation and poor financial metrics, reflected in a year-to-date return of -30.05% and a five-year decline of -84.26%, significantly underperforming the S&P 500.

As of April 29, 2021, Pacific Biosciences of California, Inc. is considered overvalued and risky, with key financial metrics indicating significant underperformance compared to peers, including a Price to Book Value of 3.73 and a year-to-date decline of -34.97%.

As of June 2, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some mildly bullish signals from MACD and KST, leading to a cautious overall outlook.

As of March 2022, the management team of Pacific Biosciences of California, Inc. includes Dr. John Milligan (Independent Chairman), Mr. Christian Henry (CEO), and several directors including Dr. Michael Hunkapiller, Ms. Kathy Ordonez, Dr. David Botstein, Mr. William Ericson, and Mr. Randall Livingston. They oversee the company's strategic direction and operations.

Pacific Biosciences of California, Inc. designs and manufactures genetic sequencing systems in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $37 million and a net loss of $426 million, with a market cap of $390.11 million.

As of Jun 18, Pacific Biosciences of California, Inc. has a market capitalization of 390.11 million, with net sales of 152.35 million and a net profit of -656.55 million over the last four quarters. Shareholder's funds are at 506.59 million, and total assets amount to 1,260.45 million.